Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

Merck (MRK) reported Q2 2025 adjusted EPS of $2.13, exceeding consensus, though revenues of $15.81 billion met estimates but declined 2% year-over-year. This revenue dip was largely attributed to a 55% plunge in Gardasil sales due to demand issues in China, which are expected to persist through late 2025, despite robust growth from Keytruda (up 9% to $7.96 billion), new products like Winrevair, and the Animal Health segment (up 11%). For 2025, Merck narrowed its revenue guidance to $64.3-$65.3 billion but raised the lower end of its adjusted EPS outlook to $8.87-$8.97, projecting a return to growth in the second half, and unveiled a new multi-year optimization initiative targeting $3 billion in annual cost savings by 2027 for pipeline reinvestment.

Analysis

Merck's second-quarter 2025 results present a bifurcated narrative, with an adjusted EPS of $2.13 beating consensus but a 2% year-over-year revenue decline to $15.81 billion. The top-line weakness is almost entirely attributable to a severe 55% plunge in Gardasil sales, driven by a $1.3 billion shortfall in China due to elevated inventory and soft demand. Management has extended the timeline for this headwind, now expecting no shipments to China through at least the end of 2025, which represents a significant and prolonged challenge. However, excluding this specific issue, the company's sales demonstrated robust underlying health with 7% growth. This strength was fueled by the continued expansion of its blockbuster oncology drug Keytruda, which grew 9% to $7.96 billion, and the successful launches of new products like Winrevair and Capvaxive. The Animal Health segment also performed strongly, with revenues up 11%. In response to the mixed performance, Merck narrowed its 2025 revenue guidance to $64.3-$65.3 billion but raised the lower end of its adjusted EPS outlook, reflecting improved profitability partly driven by a newly announced initiative to save $3 billion annually by 2027 for reinvestment into its pipeline.

Key Decisions for Investors

• Investors should parse the headline revenue decline, recognizing that the core business excluding Gardasil in China grew at a healthy 7%, driven by strong momentum in Oncology and new product launches.
• Given the stock's strong value and momentum scores but poor growth rating, it may be more suitable for value-oriented investors until the significant Gardasil headwinds in China, which are expected to persist through 2025, are resolved.
• It is prudent to monitor the sales trajectory of new drugs Winrevair and Capvaxive as key growth drivers, while considering the $1.3 billion quarterly share repurchase program as a source of support for the stock's valuation.
• Note that analyst estimates have trended downward post-earnings, reflecting the prolonged Gardasil challenges and suggesting the market may adopt a 'wait-and-see' approach despite the stock's recent outperformance.